Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429593 | 1.00 | CYP2D6 (0.35) | CYP2D6TSHRNOS2FAAHCES2 | |
| SCHEMBL9094426 | 0.88 | CES1 (0.41) | CYP2D6TSHRFAAHCES2CES1 | |
| SCHEMBL4766675 | 0.75 | FAAH (0.38) | NOS2FAAHCES2CES1LMNA | |
| SCHEMBL19611569 | 0.72 | — | — | |
| SCHEMBL642066 | 0.72 | — | — | |
| SCHEMBL642067 | 0.72 | — | — | |
| SCHEMBL19611624 | 0.71 | CYP2D6 (0.36) | CYP2D6TSHR | |
| SCHEMBL641576 | 0.71 | CYP2D6 (0.36) | CYP2D6TSHR | |
| SCHEMBL641575 | 0.71 | CYP2D6 (0.36) | CYP2D6TSHR | |
| SCHEMBL30621719 | 0.67 | FAAH (0.39) | TSHRFAAHCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | CYP2D6 622/4885TSHR 4012/4885NOS2 3573/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | CYP2D6 164/4885TSHR 3877/4885NOS2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.